Today: 20 March 2026
Subscribe
Browse Category

NASDAQ:BRZE 10 December 2025 - 17 December 2025

Braze (BRZE) Stock News Today (Dec. 17, 2025): BTIG Buy Rating, Institutional Buying, and Fresh Forecasts After an AI-Fueled Quarter

Braze (BRZE) Stock News Today (Dec. 17, 2025): BTIG Buy Rating, Institutional Buying, and Fresh Forecasts After an AI-Fueled Quarter

Braze shares rose 5.6% to $35.84 by 17:44 UTC after BTIG resumed coverage with a Buy rating and $45 price target, citing improved fundamentals. Squarepoint Ops LLC disclosed a new position in the stock, buying 116,476 shares. Trading volume reached about 1.08 million shares. The moves follow recent earnings highlighting revenue growth and AI feature expansion.
17 December 2025
Braze (BRZE) Stock on December 10, 2025: Q3 Earnings, AI Deals and a Wave of Analyst Upgrades

Braze (BRZE) Stock on December 10, 2025: Q3 Earnings, AI Deals and a Wave of Analyst Upgrades

Braze reported Q3 fiscal 2026 revenue of $190.8 million, up 25.5% year over year, and raised full-year guidance, sending shares up 2.1% to $30.65 and surging over 11% after hours. The company posted non-GAAP operating income of $5.1 million, reversing a loss last year, while total customers rose to 2,528. Shares remain down 27% for the year.
10 December 2025
···
Top U.S. Stock Gainers Today (Dec. 10, 2025): ASPC, ENVB, BDRX, HSPO, BRZE Surge Ahead of Fed Decision

Top U.S. Stock Gainers Today (Dec. 10, 2025): ASPC, ENVB, BDRX, HSPO, BRZE Surge Ahead of Fed Decision

A SPAC III Acquisition (ASPC) surged over 100% pre-market Dec. 10, trading between $25 and $31 after sharp gains in after-hours. Enveric Biosciences (ENVB) and Biodexa Pharmaceuticals (BDRX) also posted triple- and double-digit percentage gains. Major U.S. index futures were little changed ahead of the Federal Reserve’s final 2025 rate decision. Speculative micro-caps and SPACs led early trading volatility.
10 December 2025
··········

Stock Market Today

  • Amcor (AMCR) Faces Valuation Uncertainty Amid Share Price Decline and Divergent DCF Models
    March 20, 2026, 10:44 AM EDT. Amcor's stock has fallen about 22% over the past month and roughly 7% in three months, reflecting waning momentum. The packaging firm closed recently at $38.69, yet two discounted cash flow (DCF) valuations show stark contrast: one estimates fair value at $4.85, suggesting overvaluation, while another places it at $75.62, indicating significant undervaluation. The cautious DCF assumes zero growth and higher leverage pressures, while the optimistic model factors potential earnings uplift from merger integration and deleveraging improving returns. Investors face a tough call on which assumptions to trust amid conflicting signals. Overall, Amcor's valuation remains uncertain as market dynamics and internal performance factors evolve.
Go toTop